Clinical Research
Leaky blood vessels in the lung can lead to acute respiratory distress. Shutterstock
By Jalees Rehman, University of Illinois at Chicago
When you get an infection, your immune system responds with an influx of inflammatory cells that target the underlying bacteria or viruses.
These immune cells migrate from your blood into the infected tissue in order to release a cocktail of pro-inflammatory proteins and help eliminate the infectious threat.
During this inflammatory response, the blood vessel barrier becomes “leaky.” This allows for an even more rapid influx of additional immune cells. Once…
Okay, but that's not the way to extract it. fabriceh_com, CC BY-NC-SA
By Benjamin Burke, University of Hull
In the development of new drugs, taking something from nature and modifying it has been a successful tactic employed by medicinal chemists for years.
Now, with the help of nanotechnology, researchers are turning once-discarded drug candidates into usable drugs.
An estimated 40% of clinically approved drugs fall into the category where either the natural compound itself or a modified version is the approved drug. These include statins (found in bacterial secretions) used to lower…
Overcoming gaps in medical funding. nakrnsm, CC BY
By Stephanie Swift, University of Ottawa
Disease can affect any person, rich or poor. While your bank balance can’t really protect you from getting sick, it could potentially buy you – and many other patients – access to a better treatment for your disease. A new “plutocratic proposal” put forward by Alexander Masters enlists wealthy patients to both fund and participate in clinical trials alongside other patients who could benefit from an otherwise untested new treatment.
Developing a new treatment can be a long and expensive process that…
Up to 50 percent of patients with heart failure have normal or near-normal ejection fraction, termed heart failure with preserved ejection fraction (HFPEF).
The risk of death in HFPEF may be as high as in heart failure with reduced ejection fraction (HFREF), but there is no proven therapy.
Beta-blockers improve outcomes in HFREF and may be beneficial in HFPEF, but data are sparse and inconclusive, and beta-blockers are currently not indicated for treating HFPEF, according to background information in the article.
Lars H. Lund, M.D., Ph.D., of the Karolinska Institutet, Stockholm,…
A recent study compared two of the most commonly performed bariatric surgery procedures.
There are tradeoffs between the two surgical approaches in potential risks and benefits and so there has been an ongoing debate about which can achieve weight loss, with conflicting results in systematic reviews.
The two procedures were laparoscopic Roux-en-Y gastric bypass (RYGB) and adjustable gastric banding (AGB). The result was that RYGB resulted in much greater weight loss than AGB but had a higher risk of short-term complications and long-term subsequent hospitalizations. …
Each year, nearly 600,000 children die from severe, dehydrating diarrhea and millions more are hospitalized. Enterotoxigenic Escherichia coli (ETEC)
may be the first enteric illness encountered by many infants, and it causes several hundred million cases of diarrhea each year, mainly in children.
This high rate of ETEC disease in early life contributes to the faltering of infant development common in many parts of the developing world. ETEC is also the most common cause of travelers' diarrhea that affects individuals from industrialized countries visiting endemic areas. Currently, no…
Obesity
is a significant risk factor for the development of a number of diseases, but
the first that comes to mind is type 2 diabetes.
Type
2 diabetics have a greater risk of developing—and dying—from nephropathy, micro-
and macrovascular disease, impaired wound healing and neuropathy. So invoking the transitive property, obesity
should be associated with increased mortality and shorter life span. Yet a surprising number of studies have shown
that patients with a type 2 diabetes (and other diseases), live longer than
their normal weight counterparts—the so-called…
Seven Swedish women have had embryos reintroduced after receiving wombs from living donors and now one has delivered a healthy and normally developed boy, reveals the case study in The Lancet.
The uterus transplantation research project at the University of Gothenburg started in 1999 and the goal has been to enable women who were born without a womb or who have lost their wombs in cancer surgery to give birth to their own children.
Nine women in the project have received a womb from live donors – in most cases the recipient's mother but also other family members and close friends. The…
Investigators have announced discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord blood contains adult stem cells used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma.
For many patients this therapy comprises a treatment of last resort.
The researchers, directed by Dr. Guy Sauvageau, principal investigator at the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréaland hematologist at the Maisonneuve-…
Merck is discontinuing the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).
Tecemotide is an investigational MUC1 antigen-specific cancer immunotherapy that is designed to stimulate the body's immune system to identify and target cells expressing the cell-surface glycoprotein MUC1. MUC1 is expressed in many cancers, including NSCLC, and has multiple roles in tumor growth and survival. Tecemotide was being investigated in the Phase III START2, START and INSPIRE…